Skip to main content
. 2007 Nov 12;52(3):831–836. doi: 10.1128/AAC.00869-07

FIG. 1.

FIG. 1.

(A) Growth of MSSA 616 treated with vancomycin 1 g every 12 h followed by daptomycin 6 mg/kg every 24 h, with the corresponding changes in daptomycin MICs; filled squares, growth control; open circles, vancomycin 1 g every 12 h for 4 days, filled circles, daptomycin 6 mg/kg daily for 4 days; open inverted triangles, daptomycin 6 mg/kg daily for 8 days; (B) growth of the MSSA 616 growth control treated with daptomycin 6 mg/kg every 24 h; filled squares, growth control for 8 days; open circles, growth control for 4 days, filled circles, daptomycin 6 mg/kg daily for 4 days; open inverted triangles, daptomycin 6 mg/kg daily for 8 days; (C) growth of MSSA 616 treated with vancomycin 1 g every 12 h followed by daptomycin 10 mg/kg every 24 h; filled squares, growth control; open circles, vancomycin 1 g every 12 h for 4 days, filled circles, daptomycin 10 mg/kg daily for 4 days; open inverted triangles, daptomycin 10 mg/kg daily for 8 days; (D) growth of MRSA WB-1 treated with vancomycin 1 g every 12 h followed by daptomycin 6 mg/kg every 24 h; filled squares, growth control; open circles, vancomycin 1 g every 12 h for 4 days, filled circles, daptomycin 6 mg/kg daily for 4 days; open inverted triangles, daptomycin 6 mg/kg daily for 8 days. *, no increase in MIC throughout the model duration.